Colorectal News and Research

RSS
ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

PET and CT colonography combination may provide suitable alternative for detecting polyps: Study

PET and CT colonography combination may provide suitable alternative for detecting polyps: Study

Major response to preoperative therapy increases survival in pancreatic cancer patients

Major response to preoperative therapy increases survival in pancreatic cancer patients

2010 Quality Index Reports on Ontario's Cancer System

2010 Quality Index Reports on Ontario's Cancer System

Biomedical engineering professor receives Transition Career Development Award

Biomedical engineering professor receives Transition Career Development Award

EMEND indication helps women prevent CINV

EMEND indication helps women prevent CINV

HHS 'special mailing' on health law's immediate Medicare benefits sparks GOP grumbles

HHS 'special mailing' on health law's immediate Medicare benefits sparks GOP grumbles

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

UAB Comprehensive Cancer Center commemorates signing of new act for cancer screening programs

UAB Comprehensive Cancer Center commemorates signing of new act for cancer screening programs

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Routine cessation of clopidogrel in patients before colonoscopy polypectomy not necessary: Researchers

Routine cessation of clopidogrel in patients before colonoscopy polypectomy not necessary: Researchers

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech to present new data for targeted cancer medicines at 46th ASCO

British Columbians lead the way in battle against cancer

British Columbians lead the way in battle against cancer

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

152 research and training grants awarded to researchers at 93 institutions nationwide

152 research and training grants awarded to researchers at 93 institutions nationwide

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.